Norway-based seafood investor Broodstock Capital takes 50% ownership of the Norwegian sea health company Åkerblå. According to the press release from February 1st, 2019, Broodstock’s investment consists of a combination of acquisition of shares and an equity injection. In total Broodstock and current owners raised €2 M new capital available to Åkerblå. The seller was advised by SORTIS’ partner in the Globalscope M&A Advisors network – Impello Management AS, an independent and partner-owned advisory firm providing M&A advisory, strategy, and financial services.
Åkerblå is the only company in the world with accreditation status for control of fish health. It provides consulting and certification services, environment and technical operations, primarily for fish farming companies. Åkerblå also provides services to operators of wellboats and service vessels, pharmaceutical companies, institutions within research and education, as well as public sector bodies. Outside Norway, the company has operations in Iceland, Canada, and Spain.
The investment of Broodstock will give Åkerblå the opportunity to further develop and digitalize their R&D (Research and Development) department, systems and services. Broodstock’s international activity will also allow the marine health player to enter into new markets which will increase company’s international presence.
Broodstock Capital focuses on investments in small and medium-sized businesses within the seafood industry in general and in the fish supplier industry in particular. Broodstock Capital is an active investor that contributes with capital, network, experience, and financial and strategic expertise to support companies in strengthening competitive positions and profitability. According to Simen Landmark, partner at Broodstock Capital, “The company has grown steadily, year after year, and we are proud to become a co-owner. The Åkerblå investment represents the core of Broodstock Capital’s investment strategy.”